Metastatic Colon Cancer Clinical Trial
Colon cancer is one of the most common cancers in France with more than 36,000 new cases per
year. Despite significant advances in therapeutic care, the prognosis of colon cancers with
metastases remains bad. The treatment of metastatic disease is based on chemotherapy coupled
with therapeutic antibodies. The most commonly used are anti-EGFR (Epidermal Growth Factor
Receptor), which allowed a significant increase in patient survival. They are responsible
for skin toxicity in the form of an acneiform rash which can be debilitating for patients
and require discontinuation of treatment. However, this toxicity is strongly correlated with
treatment efficacy. Understanding the mechanisms of cutaneous side effects of anti-EGFR is
therefore a major challenge to treat and better understand the association with treatment
efficacy.
The objective of this study is to investigate a link between cutaneous inflammatory response
in patients treated with anti-EGFR, serum level of anti-EGFR and treatment efficacy. It will
be conducted systematic consultations dermatology, skin biopsies and blood samples in
patients treated with anti-EGFR. From biopsies, it will be searched by an infiltration of
inflammatory cells and expression of genes involved in skin inflammation.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04186117 -
Development of Clinical and Biological Database in Colorectal Cancer
|
N/A | |
| Completed |
NCT05468892 -
Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial
|
Phase 2 | |
| Recruiting |
NCT02291744 -
A Phase Ⅱ Study of XELOX Chemotherapy With or Without Surgery of Primary Lesion for Colon Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT00986661 -
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
|
Phase 1 | |
| Completed |
NCT03176485 -
Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors
|
N/A | |
| Recruiting |
NCT05983367 -
A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT03730558 -
ZETA : Prospective Observational Study
|
||
| Recruiting |
NCT06180460 -
CALM: Managing Distress in Malignant Brain Cancer
|
N/A | |
| Active, not recruiting |
NCT03251378 -
A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04737213 -
SGM-101 in Colorectal Lung Metastases
|
Phase 2 | |
| Recruiting |
NCT05714124 -
Liver Embolization Approaches for Tumor Management
|
||
| Recruiting |
NCT05396807 -
REVERT - taRgeted thErapy for adVanced colorEctal canceR paTients
|
N/A | |
| Active, not recruiting |
NCT02724202 -
Curcumin in Combination With 5FU for Colon Cancer
|
Early Phase 1 | |
| Withdrawn |
NCT03764137 -
Imaging With [89Zr]Panitumumab-PET/MRI in Patients With Newly Diagnosed Colorectal Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05848739 -
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06202183 -
Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial
|
N/A | |
| Withdrawn |
NCT01936961 -
Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors
|
N/A | |
| Not yet recruiting |
NCT06358677 -
Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Metastatic Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT03415126 -
A Study of ASN007 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT02834052 -
Pembrolizumab + Poly-ICLC in MRP Colon Cancer
|
Phase 1/Phase 2 |